These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 19507008)

  • 1. Role of salt and excipient properties on disproportionation in the solid-state.
    Guerrieri P; Taylor LS
    Pharm Res; 2009 Aug; 26(8):2015-26. PubMed ID: 19507008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disproportionation of Pharmaceutical Salts: pH
    Avdeef A
    Mol Pharm; 2021 Jul; 18(7):2724-2743. PubMed ID: 34142831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Solid-State Form on the Disproportionation of Miconazole Mesylate.
    Patel MA; Luthra S; Shamblin SL; Arora K; Krzyzaniak JF; Taylor LS
    Mol Pharm; 2018 Jan; 15(1):40-52. PubMed ID: 29202237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Metallic Stearates on Disproportionation of Hydrochloride Salts of Weak Bases in Solid-State Formulations.
    Nie H; Xu W; Ren J; Taylor LS; Marsac PJ; John CT; Byrn SR
    Mol Pharm; 2016 Oct; 13(10):3541-3552. PubMed ID: 27542728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Excipients on Salt Disproportionation during Dissolution: A Novel Application of In Situ Raman Imaging.
    Abouselo A; Rance GA; Tres F; Taylor LS; Kwokal A; Renou L; Scurr DJ; Burley JC; Aylott JW
    Mol Pharm; 2021 Sep; 18(9):3247-3259. PubMed ID: 34399050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementing quality by design in pharmaceutical salt selection: a modeling approach to understanding disproportionation.
    Merritt JM; Viswanath SK; Stephenson GA
    Pharm Res; 2013 Jan; 30(1):203-17. PubMed ID: 22918819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of solubility and dissolution of a free base and two different salt forms as a function of pH.
    Li S; Wong S; Sethia S; Almoazen H; Joshi YM; Serajuddin AT
    Pharm Res; 2005 Apr; 22(4):628-35. PubMed ID: 15846471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salt disproportionation: A material science perspective.
    Thakral NK; Kelly RC
    Int J Pharm; 2017 Mar; 520(1-2):228-240. PubMed ID: 28163222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulating weakly basic HCl salts: relative ability of common excipients to induce disproportionation and the unique deleterious effects of magnesium stearate.
    John CT; Xu W; Lupton LK; Harmon PA
    Pharm Res; 2013 Jun; 30(6):1628-41. PubMed ID: 23512680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of excipient properties, water activity, and water content on the disproportionation of a pharmaceutical salt.
    Patel MA; Luthra S; Shamblin SL; Arora KK; Krzyzaniak JF; Taylor LS
    Int J Pharm; 2018 Jul; 546(1-2):226-234. PubMed ID: 29772284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salt Disproportionation in the Solid State: Role of Solubility and Counterion Volatility.
    Thakral NK; Behme RJ; Aburub A; Peterson JA; Woods TA; Diseroad BA; Suryanarayanan R; Stephenson GA
    Mol Pharm; 2016 Dec; 13(12):4141-4151. PubMed ID: 27766882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability of pharmaceutical salts in solid oral dosage forms.
    Nie H; Byrn SR; Zhou QT
    Drug Dev Ind Pharm; 2017 Aug; 43(8):1215-1228. PubMed ID: 28276282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantifying Disproportionation in Pharmaceutical Formulations with
    Hirsh DA; Su Y; Nie H; Xu W; Stueber D; Variankaval N; Schurko RW
    Mol Pharm; 2018 Sep; 15(9):4038-4048. PubMed ID: 30016112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salt Solubility and Disproportionation - Uses and Limitations of Equations for pH
    Avdeef A; Sugano K
    J Pharm Sci; 2022 Jan; 111(1):225-246. PubMed ID: 34863819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The preparation and evaluation of salt forms of linogliride with reduced solubilities as candidates for extended release.
    Chrzanowski FA; Ahmad K
    Drug Dev Ind Pharm; 2017 Mar; 43(3):421-431. PubMed ID: 27808569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a basic organic excipient on the dissolution of diclofenac salts.
    O'Connor KM; Corrigan OI
    J Pharm Sci; 2002 Oct; 91(10):2271-81. PubMed ID: 12226854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic Barriers to Disproportionation of Salts of Weakly Basic Drugs.
    Van Duong T; Diab S; Hodnett NS; Taylor LS
    Mol Pharm; 2023 Aug; 20(8):3886-3894. PubMed ID: 37494545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disproportionation of a crystalline citrate salt of a developmental pharmaceutical compound: characterization of the kinetics using pH monitoring and online Raman spectroscopy plus quantitation of the crystalline free base form in binary physical mixtures using FT-Raman, XRPD and DSC.
    Skrdla PJ; Zhang D
    J Pharm Biomed Anal; 2014 Mar; 90():186-91. PubMed ID: 24378612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salt screening and characterization for poorly soluble, weak basic compounds: case study albendazole.
    Paulekuhn GS; Dressman JB; Saal C
    Pharmazie; 2013 Jul; 68(7):555-64. PubMed ID: 23923637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of in situ near infrared imaging and Raman mapping to study the disproportionation of a drug HCl salt during dissolution.
    Wray PS; Sinclair WE; Jones JW; Clarke GS; Both D
    Int J Pharm; 2015 Sep; 493(1-2):198-207. PubMed ID: 26200745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.